Bone marrow transplant cure for beta-thalassaemia major: initial experience from a developing country

Area of Science:

• Hematology
• Transplant Immunology
• Pediatric Hematology

Background:

• Beta-thalassemia major is a severe inherited blood disorder requiring lifelong transfusions.
• Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option.
• Sibling-matched HSCT offers a viable therapeutic strategy for eligible patients.

Purpose of the Study:

• To evaluate the outcomes of allogeneic HSCT in pediatric patients with beta-thalassemia major.
• To assess the incidence of complications and survival rates following HSCT.
• To analyze the efficacy of standard conditioning regimens in this patient population.

Main Methods:

• A cohort of 48 pediatric patients with beta-thalassemia major underwent HSCT from HLA-matched siblings.
• Standard conditioning regimens were employed prior to transplantation.
• Patients were monitored for engraftment, complications, and survival post-transplant.

Main Results:

• Engraftment was achieved in all patients.
• Overall survival and disease-free survival at 6 years post-HSCT were 79% and 75%, respectively.
• Major complications included acute graft-versus-host disease (35.4%), bacterial infections (37.5%), and fungal infections (19%).

Conclusions:

• Allogeneic HSCT is an effective treatment for beta-thalassemia major, offering high survival rates.
• Careful management of post-transplant complications, such as GvHD and infections, is essential for optimizing outcomes.
• Sibling-matched HSCT represents a valuable therapeutic approach for this condition.